同和药业：公司通过美国FDA现场检查

Core Viewpoint - The company successfully passed the FDA's cGMP inspection, which is a significant achievement reflecting its adherence to high international quality management standards and enhancing its prospects in the U.S. and international markets [1] Group 1: FDA Inspection - The company underwent an FDA cGMP inspection from August 4 to August 7, 2025, covering six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls [1] - The company achieved a zero-defect result in the FDA inspection, indicating full compliance with cGMP regulations [1] Group 2: Implications - The successful inspection is a strong affirmation of the effective operation of the company's management system [1] - This accomplishment is expected to positively impact the company's ability to expand into the U.S. market and other international markets [1]